Scarica l'app Stockscreener
25.82
22.14%
4.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$21.14
Aprire:
$24.475
Volume 24 ore:
24.04M
Relative Volume:
3.27
Capitalizzazione di mercato:
$17.96B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
4.5699
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+19.43%
1M Prestazione:
+19.48%
6M Prestazione:
+121.63%
1 anno Prestazione:
+137.53%
Intervallo 1D:
$23.97
$25.95
Intervallo di 1 settimana:
$20.98
$25.95
Portata 52W:
$8.73
$25.95
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
25.82 | 14.70B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Nigeria
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences Q3 Earnings Call Highlights - Yahoo Finance
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c - StreetInsider
Roivant Sciences Swings to Fiscal Q3 Loss as Revenue Falls - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss - marketscreener.com
Roivant Sciences Ltd. Reports Positive Phase 2 Results and Financial Performance for Q3 2025 - TradingView
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Roivant’s brepocitinib delivers rapid, sustained remissions in cutaneous sarcoidosis — first positive placebo-controlled trial - stocktitan.net
All eyes on Roivant earnings ahead of key drug trial readouts By Investing.com - Investing.com South Africa
All eyes on Roivant earnings ahead of key drug trial readouts - Investing.com Australia
Examining the Future: Roivant Sciences's Earnings Outlook - Benzinga
Understanding Momentum Shifts in (ROIV) - Stock Traders Daily
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Increases By 25.3% - MarketBeat
Market Recap: Can Roivant Sciences Ltd sustain earnings growthJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Movement Recap: Whats the fair value of Roivant Sciences Ltd stockMarket Sentiment Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday - MarketBeat
Is Roivant Sciences Ltd. benefiting from innovation trends2025 Retail Activity & Technical Buy Zone Confirmation - Mfd.ru
Revenue Check: Can Roivant Sciences Ltd generate free cash flowPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth - Seeking Alpha
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 19.57% Potential Upside in a High-Stakes Biotech Sector - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (ROIV) Movement - Stock Traders Daily
Y Intercept Hong Kong Ltd Buys 601,178 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - marketscreener.com
Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Growth Value: Will GOOS benefit from geopolitical trendsInflation Watch & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Sahm
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):